Diamedica therapeutics announces appointment of dr. richard kuntz to the board of directors

Minneapolis--(business wire)--diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of dr. richard kuntz to its board of directors effective may 30, 2023. dr. richard kuntz recently retired from medtronic plc (nyse:mdt) where he was the chief medical officer & scientific officer and a member of the executive committee. prior to that, he served as senior vice preside.
MDT Ratings Summary
MDT Quant Ranking